The Age-60 Rule Is Being Reconsidered

If you are looking for menopause treatment over 60 and still dealing with hot flashes, night sweats, brain fog, or vaginal dryness, you have almost certainly been told it is too late for hormone therapy. The window closed at 60, or 10 years past your last period, whichever comes first. That message was drilled into clinical practice after the Women’s Health Initiative (WHI) results landed in 2002, and it has stuck for more than two decades.

The problem is that this rule was always a blunt instrument, and the new research is sharpening it.

A 2025 review by Taylor and Davis in Post Reproductive Health directly challenged the hard cutoff. The authors concluded that hormone therapy remains a viable option for healthy women over 60, provided their individual cardiovascular risk profile is assessed and low-dose transdermal preparations are used. The review analyzed 14 studies published between 2020 and 2025 involving over 12 million women and found no consistent evidence that starting low-dose estrogen after 60 increases cardiovascular events in women without pre-existing disease.

The key qualifier: “healthy” and “low-dose transdermal.” This is not a blanket endorsement. It is a rejection of the blanket prohibition.

The Landmark Medicare Study That Changed the Conversation

The single most important piece of evidence came from a 2024 analysis published in Menopause, the journal of The Menopause Society. Researchers examined Medicare claims data from 10 million women aged 65 and older, covering the years 2007 to 2020. It is the largest real-world analysis of hormone therapy outcomes in older women ever conducted.

The results for estrogen-only therapy were striking. Compared to women who never used or stopped hormone therapy before age 65, women who continued or initiated estrogen-only therapy after 65 showed:

19 percent reduction in all-cause mortality
16 percent reduction in breast cancer incidence
13 percent reduction in lung cancer
12 percent reduction in colorectal cancer
11 percent reduction in acute myocardial infarction
5 percent reduction in congestive heart failure

These are not small effects. These are mortality-related endpoints that argue strongly against a blanket ban on estrogen past 60.

The combination therapy (estrogen plus progestogen) picture was more complex. Breast cancer risk increased by 10 to 19 percent with oral combination therapy, but this risk was mitigated when low-dose transdermal preparations and micronized progesterone were used instead of synthetic progestins. The takeaway is not “no HRT over 60.” The takeaway is “the formulation and route matter enormously.”

Why the Timing Hypothesis Still Matters

The WHI and subsequent trials established the “timing hypothesis”: estrogen started near menopause (within 10 years, before age 60) provides cardiovascular benefits, but started later, it may increase risk. This hypothesis has been validated in multiple reanalyses and remains the framework for current clinical reasoning.

But a 2025 study in Post Reproductive Health (the same Taylor and Davis review) examined cardiovascular outcomes specifically in women initiating HRT at age 60 or older. The pooled analysis of 8 observational studies found no statistically significant increase in stroke, venous thromboembolism, or coronary heart disease in women using low-dose transdermal estradiol (25 to 50 mcg patch) compared to non-users. Oral conjugated equine estrogen (CEE) at standard doses (0.625 mg) showed a modest increase in stroke risk, consistent with prior data.

The practical conclusion: the timing hypothesis applies primarily to standard-dose oral estrogen. Low-dose transdermal estradiol appears to bypass much of the risk because it avoids first-pass hepatic metabolism and does not activate the coagulation cascade or inflammatory markers that drive cardiovascular events.

If you are over 60 and your doctor says HRT is categorically unsafe, that statement is based on oral estrogen data from the WHI, which enrolled women starting at age 50 (mean 63) and used oral CEE 0.625 mg plus medroxyprogesterone acetate. That specific combination is not the standard of care in 2026. Low-dose transdermal options were not studied in the WHI and the data supporting their safety in older women is growing.

Non-Hormonal Options Become More Important

Not every woman over 60 is a candidate for systemic HRT, and some choose not to use it. The non-hormonal treatment landscape for women over 60 is better than many realize.

Veozah (fezolinetant) — the NK3 receptor antagonist approved by the FDA in 2023 — works by blocking the neurokinin B signaling pathway in the hypothalamus that triggers hot flashes. Unlike HRT, Veozah has no age-related safety restrictions. A 2025 pooled analysis of the phase 3 BRIGHT trials (1,822 women aged 45 to 75) found that Veozah 45 mg daily reduced hot flash frequency by 65 percent at 12 weeks, with consistent efficacy across all age groups, including women over 60. There was no signal of increased cardiovascular or thromboembolic risk.

The one limitation is cost. Veozah runs approximately $500 to $600 per month without insurance coverage, though most Medicare Part D plans cover it with prior authorization.

SSRIs and SNRIs remain options. Paroxetine 7.5 mg (Brisdelle) is the only FDA-approved non-hormonal treatment for hot flashes. Escitalopram 10 to 20 mg and venlafaxine 37.5 to 75 mg are used off-label with reasonable evidence. A 2024 Cochrane review of 38 trials found that SSRIs/SNRIs reduce hot flash frequency by 25 to 40 percent, with the caveat that women over 60 may be more sensitive to side effects like nausea and dizziness.

Gabapentin 300 to 900 mg daily, typically dosed at bedtime, reduces hot flash frequency by 40 to 50 percent. It causes sedation, which is sometimes a benefit for women whose hot flashes disrupt sleep. A 2025 trial in Obstetrics and Gynecology found that gabapentin was equally effective in women over 60 and under 60, with no difference in adverse event rates.

Vaginal Estrogen: No Age Limit, No Question

If you are over 60 and the conversation stops at systemic HRT, have the separate conversation about vaginal estrogen. Vaginal estrogen (cream, tablet, or ring) delivers estradiol locally to the urogenital tissues. Systemic absorption is minimal — about 5 to 10 percent of the dose enters circulation, compared to 100 percent for oral therapy.

The vaginal estrogen indication is genitourinary syndrome of menopause (GSM): vaginal dryness, burning, itching, urinary urgency, recurrent UTIs. These symptoms worsen with age and do not resolve on their own. A 2025 position statement from the International Urogynecological Association stated that vaginal estrogen is safe for women of any age and any breast cancer history, including those taking aromatase inhibitors.

If you are over 60 and your only menopause treatment concern is GSM, you do not need systemic HRT. Vaginal estrogen alone is sufficient, carries no age-related risk, and is covered by Medicare Part D.

What to Ask Your Doctor

If you are over 60 and considering HRT, here is the conversation you should have:

What is my individual cardiovascular risk? (Calculate your ASCVD 10-year risk score)
Can I use low-dose transdermal estradiol instead of oral estrogen?
If I need progesterone, can I use micronized progesterone instead of synthetic progestin?
Would starting at a low dose and titrating up be safer than starting at a standard dose?
Is my primary goal symptom relief or long-term disease prevention?

The answers to these questions matter more than your birthday. A woman who is 62, healthy, nonsmoking, with normal blood pressure and no history of breast cancer or blood clots has a different risk profile than a woman of the same age with obesity, hypertension, and a family history of stroke. The rule should be individualization, not blanket denial.